Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
Introduction: Although rituximab has significantly improved outcomes for patients with membranous nephropathy, response to treatment is not universal and drug resistance can occur. One mechanism of resistance is the occurrence of antidrug antibodies. Obinutuzumab and ofatumumab are humanized and hum...
Saved in:
| Main Authors: | Maxime Teisseyre, Marco Allinovi, Vincent Audard, Marion Cremoni, Giulia Belvederi, Alexandre Karamé, Matteo Accinno, Julien Duquesne, Vinod Sharma, Céline Fernandez, Kévin Zorzi, Mounir El Maï, Vesna Brglez, Sylvia Benzaken, Vincent L.M. Esnault, Alessandra Vultaggio, Harbir Singh Kohli, Raja Ramachandran, Calogero Lino Cirami, Barbara Seitz-Polski |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924034132 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ofatumumab for the management of refractory pemphigus vulgaris: A case series
by: Sera Sarsam, MBBS, BMedSc, et al.
Published: (2025-10-01) -
Corrigendum to “Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy” [Kidney International Reports Volume 6, Issue 4, April 2021, Pages 1183-1188]
by: Maxime Teisseyre, et al.
Published: (2024-07-01) -
The effectiveness and safety of ofatumumab for the treatment of pemphigus vulgaris: a cohort study based on a registry database
by: Xiwen Zhang, et al.
Published: (2025-07-01) -
COVID-19 Vaccination Response in Patients with Multiple Sclerosis Treated with Ofatumumab in the United States: A Medical Record Review
by: Rahul H. Dave, et al.
Published: (2024-10-01) -
Effector-Memory γδ T Lymphocytes Predict CMV Disease After the Withdrawal of Prophylaxis in Kidney Transplant Recipients
by: Yoann Abadie, et al.
Published: (2025-07-01)